Evidence map›Paper›PMID 35038987›Full record

ArticleBMC infectious diseases2022

A mathematical model by route of transmission and fibrosis progression to estimate undiagnosed individuals with HCV in different Italian regions.

Loreta A Kondili, Massimo Andreoni, Alfredo Alberti, Salvatore Lobello, Sergio Babudieri, Antonella De Michina, Rocco Merolla, Walter Marrocco, Antonio Craxì

Open access · goldAbstract read
In one paragraph

Article in BMC infectious diseases, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.7field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 16 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Screening strategy to advance HCV elimination in Italy: a cost-consequence analysis.The European journal of health economics : HEPAC : health economics in prevention and care · 2024
    Article
  6. Review
  7. Article
  8. Article
  9. Opportunistic co-screening for HCV and COVID-19-related services: A creative response with a need for thoughtful reflection.Liver international : official journal of the International Association for the Study of the Liver · 2022
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 7 institutions in 1 country.

Loreta A KondiliNational Center for Global Health, Istituto Superiore di Sanità, Rome, Italy. loreta.kondili@iss.it.
Massimo AndreoniUniversity of Tor Vergata, Rome, Italy.
Alfredo AlbertiDepartment of Molecular Medicine DMM, University of Padova, Padua, Italy.
Salvatore LobelloHealth Unit Euganea, Padua, Italy.
Sergio BabudieriUniversity of Sassari, Sassari, Italy.
Antonella De MichinaMedical Department AbbVie Italy, Rome, Italy.
Rocco MerollaMedical Department AbbVie Italy, Rome, Italy.
Walter MarroccoF.I.M.M.G., Rome, Italy.
Antonio CraxìGastroenterology and Liver Unit, DiBiMIS, University of Palermo, Palermo, Italy.
ABB (Italy) · ITAzienda Unità Sanitaria Locale di Ferrara · ITIstituto Superiore di Sanità · ITUniversity of Padua · ITUniversity of Palermo · ITUniversity of Rome Tor Vergata · ITUniversity of Sassari · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAlthough an increase in hepatitis C virus (HCV) prevalence from Northern to Southern Italy has been reported, the burden of asymptomatic individuals in different Italian regions is currently unknown.

methodsA probabilistic approach, including a Markov chain for liver disease progression, was applied to estimate current HCV viraemic burden. The model defined prevalence by geographic area using an estimated annual historical HCV incidence by age, treatment rate, and migration rate from the Italian National database. Viraemic infection by age group was estimated for each region by main HCV transmission routes of individuals for stage F0-F3 (i.e. patients without liver cirrhosis and thus potentially asymptomatic) and F4 (patients with liver cirrhosis, thus potentially symptomatic).

resultsBy January 2020, it was estimated that there were 409,184 Italian individuals with HCV (prevalence of 0.68%; 95% CI: 0.54-0.82%), of which 300,171 (0.50%; 95% CI: 0.4-0.6%) were stage F0-F3. Considering all individuals with HCV in stage F0-F3, the geographical distributions (expressed as the proportion of HCV infected individuals by macroarea within the overall estimated number of F0-F3 individuals and prevalence values, expressed as the percentage of individuals with HCV versus the overall number of individuals for each macroarea) were as follows: North 42.1% (0.45%; 95% CI: 0.36-0.55%), Central 24.1% (0.61%; 95% CI: 0.48-0.74%), South 23.2% (0.50%; 95% CI: 0.4-0.61%), and the Isles 10.6% (0.49%; 95% CI: 0.39-0.59%). The population of people who inject drugs accounted for 50.4% of all individuals infected (F0-F3). Undiagnosed individuals (F0-F3) were ~ 15 years younger (⁓ 50 years) compared with patients with stage F4 (⁓ 65 years), with similar age distributions across macroareas. In contrast to what has been reported on HCV epidemiology in Italy, an increasing trend in the proportion of potentially undiagnosed individuals with HCV (absolute number within the F0-F3) from South (23.2%) to North (42.1%) emerged, independent of similar regional prevalence values.

conclusionThis targeted approach, which addresses the specific profile of undiagnosed individuals, is helpful in planning effective elimination strategies by region in Italy and could be a useful methodology for other countries in implementing their elimination plans.

Indexed as

Hepatitis CHepatitis C, ChronicAntiviral AgentsHepacivirusHumansLiver CirrhosisModels, TheoreticalAntiviral AgentsHCVHepatitis C infectionMarkov chainPrevalenceUndiagnosed

Identifiers

PMID35038987
PMCPMC8761836
OpenAlexW4206156517

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.